glp-1 receptor expression papillary thyroid carcinoma of GLP-1R, GIPR, and GCGR in human tumor tissues. Tumor The science of safety: adverse

Rao Y et al

The DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial provided evidence that dapagliflozin when used in patients with heart failure with reduced ejection fraction (less than 40%) significantly reduced the risk of worsening heart failure or death from cardiovascular events regardless of presence or absence of diabetes

According to analysis by ING, GLP-1 uptake in the EU and UK combined remains around 2% of the adult population, compared with approximately 12% in the United States

The TRIUMPH clinical trial program is evaluating retatrutide for multiple indications beyond simple weight loss, including obesity with osteoarthritis, obesity with metabolic complications, type 2 diabetes, cardiovascular outcomes, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis

Ward told Science Media Centre that the study wasn't designed to assess all possible side-effects of the treatments